Loading…
Skybiotech Healthcare (BSE 512036)₹115.00+0.44%Other Textile Products
In the Jun 2026 quarter (consolidated), Skybiotech Healthcare reported sales of ₹0.48 Cr, down 79.8% from Jun 2025, and net profit of −₹0.58 Cr. For the year to Mar 2026, sales were ₹7.09 Cr and net profit −₹1.13 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 1.59 | 2.51 | 1.01 | 2.38 | 1.91 | 0.95 | 1.82 | 0.48 |
| Expenses | 0.06 | 0.05 | 1.59 | 2.84 | 2.12 | 2.32 | 2.16 | 1.42 | 2.72 | 1.03 |
| Operating Profit | −0.04 | −0.03 | 0.01 | −0.30 | −1.08 | 0.07 | −0.22 | −0.44 | −0.87 | −0.52 |
| OPM % | — | — | 1.2% | −12.4% | −106.9% | 3.3% | −12.1% | −47.0% | −48.1% | −108.3% |
| Other Income | 1.36 | 0.34 | 0.03 | 0.14 | −0.17 | 0.02 | 0.03 | 0.07 | 0.14 | 0.05 |
| Interest | 0.00 | 0.00 | 0.14 | 0.12 | −0.24 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.12 | 0.13 | 0.14 | 0.11 | 0.11 | 0.11 | 0.11 | 0.10 |
| Profit before tax | 1.33 | 0.32 | −0.21 | −0.42 | −1.20 | −0.03 | −0.32 | −0.50 | −0.86 | −0.59 |
| Tax % | 19.0% | 19.4% | 30.0% | −4.9% | −8.4% | 0.0% | 0.0% | 0.0% | −64.6% | 0.0% |
| Net Profit | 1.08 | 0.26 | −0.26 | −0.40 | −1.09 | −0.03 | −0.32 | −0.49 | −0.31 | −0.58 |
| EPS (Rs) | 5.58 | 1.32 | −1.32 | −2.05 | −5.65 | −0.11 | −1.63 | −2.52 | −1.56 | −2.99 |
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales | 0.00 | 6.95 | 7.09 | 5.16 |
| Expenses | 0.13 | 9.24 | 8.61 | 7.33 |
| Operating Profit | −0.11 | −2.24 | −1.47 | −2.05 |
| OPM % | — | −32.4% | −20.9% | −39.7% |
| Other Income | 1.99 | 0.37 | 0.30 | 0.29 |
| Interest | 0.00 | 0.02 | 0.03 | 0.00 |
| Depreciation | 0.00 | 0.53 | 0.47 | 0.43 |
| Profit before tax | 1.89 | −2.43 | −1.68 | −2.27 |
| Tax % | 18.2% | −2.1% | −32.9% | — |
| Net Profit | 1.55 | −2.38 | −1.13 | −1.70 |
| EPS (Rs) | 8.05 | −12.39 | −5.84 | −8.70 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 1.91 | 1.91 |
| Reserves | 7.05 | 6.06 |
| Borrowings | 7.18 | 8.39 |
| Other Liabilities | 3.89 | 3.01 |
| Total Liabilities | 20.03 | 19.37 |
| Fixed Assets | 11.99 | 11.51 |
| CWIP | 0.00 | 0.00 |
| Investments | 2.45 | 2.23 |
| Other Assets | 5.59 | 5.63 |
| Inventories | 1.58 | 0.79 |
| Trade receivables | 0.41 | 1.12 |
| Cash & equivalents | −0.28 | −0.60 |
| Total Assets | 20.03 | 19.37 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −1.03 | −1.53 |
| Cash from investing activity | −9.60 | 0.01 |
| Cash from financing activity | 1.25 | 1.18 |
| Net cash flow | −9.40 | −0.32 |
| Capex | 0.32 | 0.00 |
| Free cash flow | −1.38 | −1.53 |
| CFO / OP % | 46.0% | 103.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 23 | 58 |
| Inventory days | — | 74 |
| Days payable | — | 80 |
| Cash conversion cycle | 22 | 52 |
| Working capital days | −19 | −1 |
| ROCE % | — | −9.2% |
For the Jun 2026 quarter, Skybiotech Healthcare reported sales of ₹0.48 Cr, down 79.8% year on year and net profit of −₹0.58 Cr. The operating margin was −108.3%.
Skybiotech Healthcare's sales for the year to Mar 2026 were ₹7.09 Cr; over the last twelve months they were ₹5.16 Cr.
Net profit for the year to Mar 2026 was −₹1.13 Cr, and −₹1.70 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−8.70.
Skybiotech Healthcare reported borrowings of ₹8.39 Cr at Mar 2026, against cash and equivalents of −₹0.60 Cr.
Cash from operations was −₹1.53 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹1.53 Cr.